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Abstract
Blocking the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of HER2-positive
breast carcinoma cells. The hypothesis is that blocking FASN, in combination with anti-
HER2 signaling agents, would be an effective antitumor strategy in preclinical HER2+
breast cancer models of trastuzumab and lapatinib resistance. We developed and molecu-
larly characterized in vitro HER2+ models of resistance to trastuzumab (SKTR), lapatinib
(SKLR) and both (SKLTR). The cellular interactions of combining anti-FASN polyphenolic
compounds (EGCG and the synthetic G28UCM) with anti-HER2 signaling drugs (trastuzu-
mab plus pertuzumab and temsirolimus) were analyzed. Tumor growth inhibition after treat-
ment with EGCG, pertuzumab, temsirolimus or the combination was evaluated in two in
vivo orthoxenopatients: one derived from a HER2+ patient and another from a patient who
relapsed on trastuzumab and lapatinib-based therapy. SKTR, SKLR and SKLTR showed
hyperactivation of EGFR and p-ERK1/2 and PI3KCAmutations. Dual-resistant cells
(SKLTR) also showed hyperactivation of HER4 and recovered levels of p-AKT compared
with mono-resistant cells. mTOR, p-mTOR and FASN expression remained stable in
SKTR, SKLR and SKLTR. In vitro, anti-FASN compounds plus pertuzumab showed syner-
gistic interactions in lapatinib- and dual- resistant cells and improved the results of pertuzu-
mab plus trastuzumab co-treatment. FASN inhibitors combined with temsirolimus displayed
the strongest synergistic interactions in resistant cells. In vivo, both orthoxenopatients
showed strong response to the antitumor activity of the combination of EGCG with pertuzu-
mab or temsirolimus, without signs of toxicity. We showed that the simultaneous blockade
PLOSONE | DOI:10.1371/journal.pone.0131241 June 24, 2015 1 / 22
OPEN ACCESS
Citation: Blancafort A, Giró-Perafita A, Oliveras G,
Palomeras S, Turrado C, Campuzano Ò, et al. (2015)
Dual Fatty Acid Synthase and HER2 Signaling
Blockade Shows Marked Antitumor Activity against
Breast Cancer Models Resistant to Anti-HER2 Drugs.
PLoS ONE 10(6): e0131241. doi:10.1371/journal.
pone.0131241
Editor: Ramon Andrade de Mello, University of
Algarve, PORTUGAL
Received: November 7, 2014
Accepted: May 30, 2015
Published: June 24, 2015
Copyright: © 2015 Blancafort et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by the Spanish
Instituto de Salud Carlos III (ISCIII) (FIS PI11/00692,
TP) and the Spanish Ministerio de Ciencia e
Innovación (MICCIN CIT-090000-2009-10, TP and
SAF-2011-22893, EG-S), La Marató de TV3
Foundation (TP, EG-S), La Caixa Foundation (RB)
and Pfizer S.L. (TP). The University of Girona
awarded AB and AG-P with a predoctoral grant and
of FASN and HER2 pathways is effective in cells and in breast cancer models refractory to
anti-HER2 therapies.
Introduction
The human epidermal growth factor receptor 2 (HER2) is amplified or overexpressed
in* 20% of human breast carcinomas and is associated with a more aggressive phenotype and
worse prognosis [1].
HER receptors family is composed of four closely related tyrosine kinase (TK) receptors:
HER1 (EGFR), HER2, HER3, and HER4. Dimerization of HER receptors, induced by ligand
binding or receptor overexpression in the case of HER2, leads to the recruitment of several
adaptor proteins that mediate the activation of downstream signaling pathways [2, 3]. Among
them, the phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB/AKT)/mammalian target
of rapamycin (mTOR) protein and the mitogen activated protein kinases (MAPK or ERK1/2)
pathways promote cell proliferation, transformation, and survival [4, 5].
HER2-overexpressing tumors are sensitive to monoclonal antibodies (mAb) and small-mol-
ecule TK inhibitors (TKI) that interfere with HER2 function and signaling [6–8]. Trastuzumab,
a humanized mAb directed against the extracellular domain of the receptor, was the first
approved therapy for the treatment of HER2-positive (HER2+) breast cancer. Despite the con-
siderable clinical benefit provided, a large fraction of HER2+ tumors display primary or
acquired resistance to trastuzumab [9]. Lapatinib, a small-molecule TKI targeting the intracel-
lular tyrosine kinase domain of EGFR and HER2, was found to improve time to progression in
HER2 breast cancer patients who had progressed to tratuzumab [7]. Lapatinib is administered
alone or in combination with trastuzumab to abolish the activation of HER2-downstream
pathway. But unfortunately, some tumors develop lapatinib resistance and also resistance
against the combination of both drugs [10]. The molecular mechanisms leading to trastuzumab
and lapatinib resistance has been extensively studied [11]. These include for example in vivo
conversion of HER2+ to HER2- carcinoma after neoadjuvant trastuzumab [12], predominance
of the constitutively active HER2 form (p95HER2) [8], overexpression or hyperactivation of
other HER family receptors or its ligands [13], amplification of the PI3K/AKT/mTOR pathway
by loss of phosphatase and tensin homolog (PTEN) [14], gain-of-function mutation in
PI3KCA (encoding the PI3K catalytic isoform p110α) [15] and AKT mutations or amplifica-
tions [16].
Fatty acid synthase (FASN) is a homodimeric multienzymatic protein that catalyzes de
novo synthesis of long-chain fatty acids [17]. Blocking FASN activity causes in vitro and in vivo
anticancer activity in several overexpressing FASN human carcinomas [18, 19]. The proposed
oncogenic properties of FASN seem to be the result of an increased activation of HER2 and its
dowstream related PI3K/AKT/mTOR and MAPK signaling pathways [18–20]. FASN can also
inhibit the intrinsic pathway of apoptosis [21], may also contribute to modulation of the mem-
brane lipid rafts that anchor HER2 [22] and has been recently proposed as a direct target of
p53 family members, including p63 and p73 [23]. In the past, FASN inhibitors with antitumour
activity have been limited by either cross-activation of β-oxidation, which produces in vivo
anorexia and body weight loss [24, 25], or low potency [26, 27]. We have developed new poly-
phenolic anti-FASN compounds that exhibit in vitro and in vivo anticancer activity improving
the antitumor efficacy and the toxic effects of classical FASN inhibitors, in HER2+ breast can-
cer cells and mouse models [19, 28, 29]. Among of them, G28UCM has shown a strong
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antitumor effect, alone or in combination with anti-HER drugs, in HER2+ breast cancer cells
and on breast cancer cells resistant to trastuzumab [29].
In this study, we have investigated the anticancer activity of the classical FASN inhibitor epi-
gallocathequin-3-gallate (EGCG) and G28UCM, as single agents or in combination with pertu-
zumab and temsirolimus, in our developed trastuzumab (SKTR), lapatinib (SKLR) and
trastuzumab plus lapatinib (SKTLR) resistant HER2+ breast cancer models. In addition, we
analyzed the antitumor activity of EGCG, alone or in combination, in two in vivo xenografts:
one HER2+ patient and another from a HER2+ patient who fail to respond to trastuzumab and
lapatinib therapies.
Materials and Methods
Cell culture and development of long-term resistant breast cancer cells
SKBr3 (SK) breast carcinoma cells were obtained from Eucellbank (University of Barcelona)
[30]. SKBr3 cells were routinely grown in McCoy’s (Gibco) supplemented with 10% FBS
(HyClone Laboratories), 1% L-glutamine, 1% sodium pyruvate, 100 U/mL penicillin, and
100 μg/mL streptomycin (Gibco). Trastuzumab-resistant SK cells (SKTR) were developed by
exposing SK cells continuously to trastuzumab (Herceptin, Hoffmann-La Roche Pharma),
starting with 1μM concentration for three months of exposure and increasing the concentra-
tion up to 2 μM for a 12 months period, as we previously described [29]. Thus, cells resistant to
trastuzumab were maintained in 2 μM trastuzumab, a concentration at which SK parental cells
were not viable. To develop lapatinib-resistant cells (SKLR), SK cells were treated for one
month with an initial dose of 1.5 μM of lapatinib (GW572016; Tykerb, GlaxoSmithKline) and
after one month the dose of lapatinib was increased up to 3 μM for 12 months as we described
[29], a concentration at which SK parental cells were not viable. To develop lapatinib plus tras-
tuzumab resistant cells (SKLTR), SKLR were co-cultured with lapatinib 3 μM and trastuzumab
1μM and after one month in culture the dose of trastuzumab was increased up to 2 μM. Cells
were co-cultured with lapatinib and trastuzumab for 12 months. SKLTR cells were mantained
with 3 μM of lapatinib and 2 μM of trastuzumab. Trastuzumab, lapatinib and trastuzumab plus
lapatinib resistance was confirmed by dose-response studies using the standard colorimetric
MTT assay as we describe in S1 File. Cell line authentication was performed with STR analysis
in an external laboratory (Genetica DNA Laboratories) (S2 File). Parental and resistant cells
shared 100% STR profile with SKBr3 cell line.
HER2-Fluorescent in situ hybridization (FISH)
HER2 FISH pharmDX Kit (Dako) was used to quantify HER2 gene copy number in parental
and resistant cells as previously described [29]. The ratio of average HER2 to average CEN17
copy number was calculated for twenty nuclei. Gene amplification was defined when the FISH
ratio HER2 signal / CEN17 signal was> 2.
Western blot analysis of tumor and cell lysates
Parental (SK) and resistant (SKTR, SKLR and SKLTR) cells were serum-deprived for 24 hours
in 0.5% FBS-medium, then were lysed with ice-cold in lysis buffer (Cell Signaling Technology,
Inc.) containing 1 mM EDTA, 150 mMNaCl, 100 μg/mL PMSF, 50 mM Tris-HCl (pH 7.5),
protease and phosphatase inhibitor cocktails (Sigma). Equal amounts of protein were heated in
LDS Sample Buffer and Sample Reducing Agent (Invitrogen) for 10 min at 70°C, separated on
SDS-polyacrylamide gel (SDS-PAGE), and transferred to nitrocellulose membranes. Blots were
incubated overnight at 4°C with the following primary antibodies: rabbit polyclonal antibodies
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against FASN (Assay Designs; 905-069; dilution 1:1500), HER2/ErbB2/Neu (C-18) (Santa
Cruz Biotechnology Inc.; SC-284; dilution 1:1000), EGFR (Cell Signaling Technology Inc.;
#2232; dilution 1:200), phospho-EGFRTyr1068 (Cell Signaling Technology Inc.; #2234; dilution
1:200), AKT (Cell Signaling Technology Inc.; #9272; dilution 1:500), p44/42 MAPK (Erk 1/2)
(Cell Signaling Technology Inc.; #9102; dilution 1:500), and phospho-mTORSer2448 (Cell Sig-
naling Technology Inc.; #2971; dilution 1:500); rabbit monoclonal antibodies against HER3/
ErbB3 (Cell Signaling Technology Inc.; #4754; dilution 1:200), phospho-HER3/ErbB3Tyr1289
(Cell Signaling Technology Inc.; #4791; dilution 1:200), HER4/ErbB4 (Cell Signaling Technol-
ogy Inc.; #4795; dilution 1:200), phospho-HER4/ErbB4Tyr1284 (Cell Signaling Technology Inc.;
#4757; dilution 1:200), phospho-AKTSer473 (Cell Signaling Technology Inc.; #4058; dilution
1:200) and mTOR (Cell Signaling Technology Inc.; #2983; dilution 1:500), and mouse mono-
clonal antibodies against phospho-p44/42 MAPK (Erk 1/2)Thr202/Tyr204 (Cell Signaling Tech-
nology Inc.; #9106; dilution 1:500) and phospho-c-erbB-2 (HER-2/neu)Tyr1248 (Thermo
Scientific Inc.; MS-1072-P1; dilution 1:200). Antibodies were diluted in blocking buffer (2.5%
powdered-skim milk in phosphate buffered saline solution with 0.05% Tween 20, PBS-T
(10 mM Tris-HCL pH 8,0 and 150 mMNaCl). Then, blots were incubated with mouse and
rabbit peroxidase-conjugated secondary antibody and revealed using a commercial kit (Super
Signal West Pico or Super Signal West Femto chemiluminescent substrate (Thermo Scientific
Inc.) or Immobilon Western HRP Substrate (Millipore). Blots were re-proved with a mouse
monoclonal antibody against β-actin (Santa Cruz Biotechnology Inc.) as control of protein
loading and transfer. Western blot analyses were repeated at least three times and representa-
tive results are shown (S3 File).
Genetic analysis of PI3K mutations
DNA was extracted from SK, SKTR, SKLR and SKLTR cells following commercial protocols
(QIAamp DNA blood Mini kit, Qiagen). Subsequently, polymerase chain reaction (PCR) was
used to amplify the PI3K gene (NM_006218) (NCBI-National Center for Biotechnology Infor-
mation). PCR products were purified using ExoSAP-IT (Isogen Life Science), and the analysis
of the exonic and intron-exon regions was performed forward/reverse by direct sequencing
(Genetic Analyzer 3130XL, Applied Biosystems).
Quantitative real-time PCR analysis of HER ligands
Parental and resistant cells were washed with PBS and trypsinized. Total-RNA from each sam-
ple was isolated using RNeasy mini kit (Qiagen). RNA was reverse-transcribed into comple-
mentary DNA (cDNA) using High Capacity cDNA Archive Kit (Applied Biosystems). HER
ligands expression (EGF, TGF-α, AR, BTC, EREG, NRG-1 and HB-EGF) was quantified by
real-time PCR using a pre-designed, gene-specific TaqMan probe and primer sets (TaqMan
Gene Expression assays, Applied Biosystems). Quantitative PCR was performed using TaqMan
One-Step Universal Master Mix (Applied Biosystems) and 7300 Real-Time PCR system
(Applied Biosystems). All samples were tested in triplicate. Relative quantification of the
mRNA level (μg/ml) of HER ligands was carried out. Then, mRNA level was normalized to the
housekeeping gene TATA box binding (TBP) protein.
Cell invasion and adhesion assays
Parental and resistant cells were overnight FBS-starved (0.5% FBS-medium) before carrying
the CytoSelect 24-well cell invasion assay and the CytoSelect 48-well cell adhesion assay (Cell
Biolabs), following the manufacturer’s instructions.
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Growth inhibition and dose-response studies
Parental and resistant cells were plated out at a density of 5 x 103 cells/100 μL/well in 96-well
microtitre plates. Following overnight cell adherence fresh medium along with the cor-
responding concentrations of HER2 inhibitors (trastuzumab and pertuzumab [2C4, Perjeta,
Genentech]), FASN inhibitors (EGCG [Sigma] and 1,3-bis((3,4,5-thilhydroxybenzoil)oxy)
naphthalene (G28UCM) synthesized as we previously described [19]) or mTOR inhibitor
(temsirolimus; CCI-779, Torisel, Pfizer) was added to the cultures. Pertuzumab (5 μg/ml)
was combined with trastuzumab (20 μM) or FASN inhibitors (60 μM of EGCG or 5 μM of
G28UCM) for 5 days. For temsirolimus drug-combination experiments cells were treated for 2
days with a dose curve concentration of EGCG (5–300 μM) or G28UCM (0.1–15 μM) plus
fixed concentrations of temsirolimus (0.05, 0.1, 0.5 and 1 μM). Same treatments were assessed
in monotherapy. Following treatment, media was replaced by drug-free medium (100 μL/well)
containing MTT (3,4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide, Sigma) solu-
tion, and incubation was prolonged for 3 h at 37°C. Formazan crystals formed by metabolically
viable cells were dissolved in DMSO (100 μL/well) and absorbance was determined at 570 nm
in a multi-well plate reader (Model Anthos Labtec 2010 1.7). Using control OD values (C) and
test OD values (T), % of cell proliferation inhibition (% cpi) was calculated from the equation,
100 - [(T x 100) / C]. Data presented are from three separate wells per assay and the assay was
performed at least three times. Combinatorial effects were evaluated using the ratio of % cpi
produced by each drug alone vs% cpi produced by drug combination (% cpi drug / % cpi com-
bination), average of both ratios was calculated to know the effect of combination compared
with both compounds alone. Interactions of G28UCM and EGCG with temsirolimus were also
evaluated by the isobologram method as we previously published [29]. Briefly, the concentra-
tion of one agent producing a 30% inhibitory effect is plotted on the horizontal axis, and the
concentration of another agent producing the same degree of effect is plotted on the vertical
axis; a straight line joining these two points represents zero interaction (addition) between two
agents. The experimental isoeffect points were the concentrations (expressed relative to the
IC30 concentrations) of the two agents that when combined kill 30% of the cells. When the
experimental isoeffect points felt below that line, combination effect of the 2 drugs was con-
sidered to be supra-additive or synergistic, whereas antagonism occurs if the experimental
isoeffect points lie above it. Within the designed assay range, a set of isoeffect points was gener-
ated because there were multiple FASN inhibitors and anti-target agent concentrations that
achieved the same isoeffect. A quantitative index of these interactions was provided by the
equation Ix = (A/a) + (B/b), where, for this study, a and b represent the respective concentra-
tions of FASN inhibitors (EGCG or G28UCM) and anti-mTOR agent (temsirolimus) required
to produce a fixed level of inhibition (IC30) when administered alone, and A and B represent
the concentrations required for the same effect when the drugs were administered in combina-
tion, and Ix represents an index of drug interaction (interaction index). Ix values of<1 indicate
synergism, a value of 1 represents additivism, and values of>1 indicate antagonism. For all
estimations of Ix, we used only isobolos where intercept data for both axes were available.
In vivo studies: human breast tumor PDX (patient-derived xenografts)
experiments
Tumor chunks from HER2+ breast cancer patient and HER2+ patient who relapsed after tras-
tuzumab and lapatinib-based treatment were orthotopically implanted into both inguinal
cleared mammary fat pads of NOD/SCID (Harlan Laboratories, Inc.) or NSG (NOD/SCID;
IL2Rγ−/−) mice (Charles River Laboratories). When tumors reached 30–60 mm3, animals
were randomized into treatment-groups. Each group received a single intraperitoneal (i.p.)
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injection (maximum of 0.2 mL) of control (vehicle alone 3d/wk), 30 mg/kg EGCG 3d/wk,
30 mg/kg pertuzumab 1d/w, 10 mg/kg temsirolimus 1d/w, or combination of EGCG + pertuzu-
mab and EGCG + temsirolimus. Tumor xenografts were measured with calipers and tumor
volumes were determined using the formula: (π/6 x (v1 x v2 x v2)), where v1 represents the
largest tumor diameter, and v2 the smallest one. Body weight was registered 2–3 d/wk. At the
end of the experiment, animals were weighed and then euthanized using CO2 inhalation.
Tumors and serum were stored at -80°C. Lung, heart, liver, kidneys and tumor were fixed with
formalin (S1 File). Apoptosis in control and treated tumors was analyzed by fluorescent
TUNEL assay. Briefly, DNA fragmentation by terminal deoxynucleotidyl transferase-mediated
dUTP-biotin nickend labeling (TUNEL) was performed according to the manufacturer’s
instructions (in situ cell death detection, Roche). Nuclei contrast was performed using fluores-
cent DAPI staining (40-60-Diamidino-2- phenylindole, Sigma). Pictures shown are representa-
tive of two samples per each treatment group.
Ethics Statement
Experiments were conducted in accordance with guidelines on animal care and use established
by Biomedical Research Institute of Bellvitge (IDIBELL) Institutional Animal Care and Scien-
tific Committee (protocol EST-FOR-070.03). All mice were maintained in a specific pathogen-
free AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care
International) International accredited facility in accordance with Spanish and European regu-
lations with controlled light/dark cycle, temperature, and humidity. As approved by the above-
mentioned committee, all surgery was performed under inhaled isoflurane anesthesia, burpre-
norphine was administered as analgesic to mice after surgery, all mice were euthanized with
CO2 asphyxiation at the end of the experiment or when tumors reached 1 cm of diameter, and
all efforts were made to minimize suffering.
Statistical analysis
Data were analyzed by Student t test when comparing two groups or ANOVA using a Bonferr-
ony test as post-test when comparing more than 2 groups. Statistical significant levels were
p< 0.05 (denoted as ), p< 0.01 (denoted as ) and p< 0.001 (denoted as ). p-value is
shown in results when significance is reached (p< 0.05). All data are means ± standard error
(SE). All observations were confirmed by at least three independent experiments.
Results
Characterization of trastuzumab (SKTR), lapatinib (SKLR) and lapatinib
plus trastuzumab-resistant (SKLTR) breast cancer cells
As preclinical models of acquired resistance to anti-HER2 drugs, we developed a panel of resis-
tant HER2+ breast cancer cells (SK) with long-term (12 months) and high drug concentration
exposure of trastuzumab (SKTR), lapatinib (SKLR) and lapatinib plus trastuzumab (SKLTR)
(S1 Fig), following Nahta R et al. methodology [31]. To elucidate molecular mechanisms
regarding acquired resistance in our developed resistant cells (SKTR, SKLR and SKLTR) we
first examined HER2 gene amplification by fluorescence in situ hybridation. The ratio of the
average HER2 gene copy number to the average CEP17 gene copy number in SK was 3.53 and
in SKTR, SKLR and SKLTR was 6.32, 3.99 and 4.84, respectively (Fig 1A). These results
showed that resistant cells possess HER2 amplification, similar as parental cells.
We next analyzed changes in HER family protein receptors and their downstream proteins
related to PI3K/AKT/mTOR and MAPK/ERK1/2 pathways. As shown in Fig 1B, trastuzumab
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Fig 1. Characterization of parental (SK) and resistant (SKTR, SKLR and SKLTR) cells. (a) HER2 gene copy number is maintained in resistant cells.
FISH, fluorescence in situ hybridization; HER2/CEN17 > 2 indicates HER2 gene amplification. (b) Resistant cells showed changes in the expression and
activation of EGF family receptors but maintained downstream pathways activation (ERK1/2/AKT/mTOR) without affecting FASN protein expression levels.
Protein expression and activation of EGFR family receptors pathways was analyzed byWestern Blot. Gels shown are representative of those obtained from
3 independent experiments. (c)Mutational status of PIK3CA gene in resistant cells. Trastuzumab-resistant cells (SKTR) acquire the activating
PIK3CA_E545Kmutation and lapatinib- and lapatinib plus trastuzumab-resistant cells (SKLR and SKLTR) acquire the activating PIK3CA_E542Kmutation.
DNA sequencing of PI3K exon 9 of the resistant cells compared with the parental cells. (d) EGFR ligands are increased in resistant cells. Changes in the
expression of each ligand by acquisition of resistance were assessed by real-time PCR and values were normalized against the corresponding mRNA
expression of TBP constitutive gene. Then, ligands expression of trastuzumab-, lapatinib- and trastuzumab plus lapatinib-resistant cells (SKTR, SKLR,
SKLTR) was compared to parental cells (SK). The bars indicate the mean fold change ± SE of two independent quantifications. Bars over the dotted line
indicate an increase in the gene expression compared to the control cells, while bars under the dotted line represent impaired gene expression after the
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resistant cells (SKTR) had a significant increase in EGFR and phosphorylated EGFR proteins
and to a lesser extent in p-ERK1/2 and AKT, with a noticeably decreased p-HER2 protein and
reduced levels of HER3, p-HER3 and p-AKT compared to SK control cells. Cells resistant to
lapatinib (SKLR) showed a great increase in p-EGFR and p-HER2 proteins and a slightly
increase in p-ERK1/2, whereas levels of HER3, p-HER3 and p-AKT were decreased compared
to SK control cells. Lapatinib plus trastuzumab-resistant cells (SKLTR) showed increased
expression of phosphorylated forms of HER2, EGFR, HER4 and AKT compared to its control
lapatinib-resistant cells (SKLR). Interestingly, no significant changes in mTOR and p-mTOR
protein levels were observed in any resistant cells compared to SK cells. Regarding FASN,
which transcription and translation is mediated by HER2 signaling pathway [29, 32], protein
expression levels showed no changes in resistant cells.
Mutation of PI3K is another described mechanism of resistance to anti-HER2 treatments.
We found low incidence of activating mutations in the p110α catalytic subunit of PI3K
(PIK3CA) in all resistant cells. We detected the PIK3CA_E545K mutation in SKTR cells and
the PIK3CA_E542K mutation in SKLR and its derivative SKLTR (Fig 1C).
Changes in crosstalk between receptors of HER family prompted us to investigate the
mRNA expression profile of several HER activating ligands by real-time PCR in resistant and
parental cells (Fig 1D). HB-EGF (heparin-binding EGF-like growth factor) mRNA expression
was significantly up-regulated (more than 3-fold; p-value: 0.012) in trastuzumab resistant cells
(SKTR) compared to SK control cells. In contrast, AR (amphiregulin; p-value: 0.024) was
down-regulated, and TGF-α (transforming growth factor-α) and BTC (beta-cellulin) expres-
sion was slightly down-regulated in SKTR versus SK cells. Otherwise, SKLR cells up-regulated
EGF (epidermal growth factor) (1.5 folds compared with SK; p-value: 0.045), TGF-α (nearly 3
folds; p-value: 0.044), EREG (epiregulin) (4.5 folds) and HB-EGF (more than 2.5 folds; p-value:
0.014), but down-regulated AR and BTC expression in about 0.5 folds, comparing with SK.
Double-resistant (SKLTR) cells showed a great up-regulation in almost all ligands (EGF in
more than 6 folds, AR in almost 5 folds (p-value: 0.011), BTC and EREG in 3 folds and
HB-EGF almost 2 folds), only TGF-α was slightly down-regulated in 0.5 folds, comparing with
SK cells.
Since some studies reported that HER2 mediates tumor growth and metastasis [33, 34], and
several molecular changes (that could alter tumor aggressiveness) occurred on HER2 and its
downstream pathways, we conducted experiments to evaluate such hallmark by measuring cell
invasion and adhesion to extracellular matrix (opening metastatic event) capacities of our
developed resistant cells (Fig 1E). Moreover, several types of resistance such as some chemo-
therapeutic drugs and multidrug resistance (combining several natural chemotherapeutic
drugs) have been associated with cancer invasion and metastasis [35, 36]. Hence, we wanted to
know if mechanisms of resistance in our anti-HER2 resistant models also turned to a more
aggressive phenotype of tumor cells. SKTR cells showed a huge significantly increased capacity
to adhere to extracellular matrix proteins: fibronectin (2.9 fold-change; p-value: 0.002), collagen
I (3.3 fold-change; p-value: 0.013), collagen IV (4.4 fold-change; p-value: 0.043), laminin I (5.8
fold-change; p-value: 0.001) and a slightly increase in fibrinogen adherence (1.3 fold-change)
compared with SK parental cells. SKLR cells had a remarkable increased adherence to fibronec-
tin (1.5 fold-change; p-value: 0.031), collagen I (2 fold-change; p-value: 0.003) and collagen IV
treatment. (e) Cellular adhesion and invasion capacity are increased in resistant cells. Fold-changes of resistant cells (SKTR, SKLR and SKLTR) respect to
wild type SKBr3 cells (SK) in adhering to extracellular matrix proteins or in invasion capacity. Fold changes were assessed with adhesion or invasion kit
assays. Experiments were performed at least twice. * (p 0.05) and ** (p 0.01) indicate levels of statistically significant difference compared with parental
cells.
doi:10.1371/journal.pone.0131241.g001
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(2.3 fold-change; p-value: 0.005) and to a lesser extent to laminin I (1.4 fold-change) and fibrin-
ogen (1.1 fold-change) compared with SK cells. SKLTR showed a significant increased capacity
to adhere to fibronectin (1.6 fold-change; p-value: 0.011) and collagen I (1.2 fold-change; p-
value: 0.030), a slight adherence to laminin I (1.4 fold-change) and fibrinogen (1.3 fold-
change), whereas adhesion to collagen IV was almost unchanged, compared to SK. Regarding
the invasion capacity, both SKTR and SKLR cells showed relevant increased capacity than SK
cells [1.4 and 1.6 (p-value: 0.011) folds more, respectively]. Conversely, SKLTR cells showed
half invasion capacity (0.5 folds; p-value: 0.025) than SK cells (Fig 1E).
In vitro cell growth interactions between HER2 inhibitors, trastuzumab
and pertuzumab, in SK, SKTR, SKLR and SKLTR
SKTR, SKLR and SKLTR cells maintained HER2 protein expression levels similar to parental
cells (Fig 1B). Therefore, we first checked the effects of the HER2-dimerization inhibitor, pertu-
zumab, in comparison with trastuzumab in resistant cells. As shown in Fig 2, 5 μg/ml of pertu-
zumab and 20 μM of trastuzumab were needed to achieve 50% inhibition of cell proliferation
(% cpi) of SK parental cells. Same drug concentrations in SKTR, SKLR and SKLTR showed sig-
nificant resistance to pertuzumab and trastuzumab, compared with SK cells. Pertuzumab only
reached 27.8% (p-value: 0.004), 38.8% (p-value: 0.041) and 19.6% (p-value: 0.001) of cpi in
SKTR, SKLR and SKLTR, respectively. Similar inhibitory pattern displayed trastuzumab in
SKTR (19.9%; p-value: 0.000), SKLR (32.1%; p-value: 0.022) and SKLTR (15.4%; p-value:
0.000) cells.
Co-treatment of resistant cells with trastuzumab plus pertuzumab did not increase cytotoxic
effect in SKTR (25.7% cpi; p-value: 0.008), neither in SKLR (38.3% cpi; p-value: 0.023) cells.
But, co-treatments effect in SK and SKLTR significantly improved the inhibitory effect up to
63.1% in SK cells (p-value: 0.007 compared with trastuzumab), and 52.5% in combined treat-
ments (p-valuePertuzumab: 0.001 compared with pertuzumab and p-valueTrastuzumab: 0.000 com-
pared with trastuzumab).
In vitro cell growth interactions between FASN inhibitors and
pertuzumab in SK, SKTR, SKLR and SKLTR
Since targeting only HER2 was far from obtaining desired results in resistant models, we
decided to explore dual targeting pharmacological strategies. Because FASN showed similar
expression levels in parental and resistant cells (Fig 1B), this could be a candidate target to
overcome anti-HER2 resistance. Thus, we conducted series of combinatory experiments to
evaluate the inhibitory effect of EGCG and G28UCM alone and in combination with pertuzu-
mab in SK, SKTR, SKLR and SKLTR cells. The natural anti-FASN compound EGCG had simi-
lar cytotoxic effect in parental and resistant cells. IC50 values ranged from 206 ± 18.7 μM to
229 ± 29.4 μM in SK, SKTR, SKLR and SKLTR cells. G28UCM, the synthetic derivative of
EGCG, improved the cytotoxic effect of EGCG in all cell lines. IC50 value of G28UCM in
parental and resistant cells ranged from 9 ± 1.5 μM to 19 ± 2.1 μM (S1 Table). In addition and
according to our previous results in HER2+ parental cells, EGCG and G28UCM induced apo-
ptosis (cleavage of PARP) in resistant cells (S2 and S3 Figs).
Results regarding pertuzumab combinatory experiments with EGCG and G28UCM are
shown in Fig 3A. Pertuzumab (5 μg/ml) combined with anti-FASN compounds (60 μM of
EGCG or 5 μM of G28UCM) increased cpi in parental and resistant cells. Ratios of cpi induced
for treatments alone versus inhibition induced for co- treatment was less than 1 in all combina-
tory experiments. In SK cells, ratio of mono-treatments/combination was 0.34. In SK, SKLR
and SKTR, ratio of mono-treatments/combination was 0.34, 0.82 and 0.62, respectively. In
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SKLTR, monotreatments/combination ratio was 0.31. In this case, pertuzumab plus EGCG
combination significantly improved effects of each treatment alone (which is graphed as 1 in
Fig 3; p-value compared with 1: 0.036). G28UCM plus pertuzumab slightly improved EGCG plus
pertuzumab inhibitory effects in SKTR cells (0.69 when combined with G28UCM compared
with 0.82 in EGCG case) (Fig 3A).
Together, these data show that the co-exposure of the FASN inhibitors, EGCG and
G28UCM, with pertuzumab in parental and resistant HER2+ breast cancer cells is more active
than either of the drugs used as a single agent.
In vitro cell growth interactions between FASN inhibitors and
temsirolimus in SK, SKTR, SKLR and SKLTR
In our resistant cells we showed changes in EGF family receptors expression and activation
without changes in mTOR expression and activation, neither in FASN expression. Since resis-
tant cells express similar levels of mTOR and FASN as same as parental cells, we tested the apo-
ptotic (PARP cleavage) effect of inhibiting mTOR (temsirolimus) and FASN (EGCG) in
combination with trastuzumab and/or lapatinib. Temsirolimus or EGCG did not recovered
trastuzumab and/or lapatinib sensitivity in resistant cells (S3 Fig). Therefore we conducted
experiments to evaluate the inhibitory effect of temsirolimus (mTOR inhibitor) alone and in
combination with anti-FASN compounds (EGCG and G28UCM) in the developed resistant
HER2+ models (SKTR, SKLR and SKLTR).
Temsirolimus alone displayed a potent anti-proliferative effect in parental and resistant
cells. IC50 concentration ranged from 9 ± 0.9 μM to 11 ± 0.4 μM in resistant models (S1 Table).
Temsirolimus (0.05, 0.1, 0.5 and 1 μM) combined with anti-FASN compounds (60 μM of
EGCG or 5 μM of G28UCM) for 2 days increased cpi in parental and resistant cells. Mean
ratios of cpi induced for each treatment alone versus inhibition induced for co-treatment is
shown in Fig 3B EGCG plus temsirolimus ratio was similar in parental and resistant cells
Fig 2. Pertuzumab plus trastuzumab combination improves effects in SK and SKLTR.Cells were
treated with trastuzumab (20 μM), pertuzumab (5 μg/ml) and the combination of both for 5 days. Results were
determined using an MTT assay and are expressed as the percentage of cell proliferation inhibition from
three independent experiments performed in triplicate. Columns represent % of cell proliferation inhibition
after trastuzumab or pertuzumab exposure and bars SE. * (p 0.05), ** (p 0.01) and *** (p 0.001)
indicate levels of statistically significant difference compared with effect of the same drug in SKBr3 cells or
compared with drugs administered alone (dashed line).
doi:10.1371/journal.pone.0131241.g002
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(from 0.48 to 0.52 and all significantly different from mono-treatments effect; graphed as 1).
When temsirolimus was combined with G28UCM, combinatorial effect was almost doubled
(ratios were from 0.22 to 0.30; all p-values< 0.000).
These results were confirmed by the isobologram method, using a series of isobologram
transformations of multiple dose-response curves at an effect level of 30% (IC30), an statistical
analysis that we have used previously [29]. Simultaneous treatment of SK, SKTR, SKLR and
SKLTR cells with EGCG and temsirolimus resulted in a strong synergistic interaction index
(0.84< Ix< 0.94). Combination of G28UCM plus temsirolimus had an enhanced synergistic
interaction index in parental and resistant cells (0.36< Ix< 0.58), shown in S1 Table.
Effects of EGCG plus temsirolimus compared with mono-treatments and other combina-
tions (EGCG plus pertuzumab and pertuzumab plus trastuzumab and/or lapatinib) on FASN
and mTOR expression were also assessed by western blot analysis (see S4 Fig). No significant
inhibition in FASN and mTOR protein levels was seen in any treatment except in the case of
EGCG plus temsirolimus combination. EGCG plus temsirolimus completely abolished mTOR
expression in SKTR, SKLR and SKLTR resistant cells.
Fig 3. FASN inhibitors improve pertuzumab and temsirolimus activity in parental and resistant cells.
(a)Cells were treated with pertuzumab (5 μg/ml) combined with EGCG (60 μM) or G28UCM (5 μM) for 5
days. Results were determined using an MTT assay and are expressed as ratio of inhibition of cell
proliferation induced for each treatment alone versus inhibition induced for co- treatment from three
independent experiments performed in triplicate. Dashed lines represent the effect of each drug alone, ratio
1. (b)Cells were treated with temsirolimus (0.05, 0.1, 0.5 and 1 μM) combined with EGCG (60 μM) or
G28UCM (5 μM) for 2 days. Results were determined using an MTT assay and are expressed as ratio of
inhibition of cell proliferation induced for each treatment alone versus inhibition induced for co- treatment from
three independent experiments performed in triplicate and with several temsirolimus concentrations. Dashed
lines represent the effect of each drug alone, ratio 1. * (p 0.05), ** (p 0.01) and *** (p 0.001) indicate
levels of statistically significant difference compared with drugs administered alone.
doi:10.1371/journal.pone.0131241.g003
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These data show that co-exposure of temsirolimus with FASN inhibitors, EGCG and
G28UCM, display a more potent synergistic effect in HER2+ parental and resistant cells than
either of the drugs used as a single treatment.
Antitumor activity of EGCG in combination with pertuzumab and
temsirolimus in HER2+ sensitive and resistant patient derived
xenografts
To better recapitulate the clinical setting we extent our findings in vivo evaluating the antitu-
mor activity of pertuzumab, temsirolimus and EGCG and the combination in a HER2+ PDX
model (HER2-PDX) and in a trastuzumab plus lapatinib-resistant HER2+ PDX (HER2-PDXR)
model. Both PDX models showed similar HER2, mTOR and FASN expression levels as the in
vitro parental and resistant cellular models (S5 Fig). EGCG (30 mg/kg for 3d/w) and pertuzu-
mab (30 mg/kg/once weekly), as single agents, reduced tumor growth in the HER2-PDX model
after 24 days of treatment. Control animals achieved a median tumor growth of 461.0 ± 65.6
mm3 whereas EGCG significantly reduced tumor growth to 247.6 ± 45.0 mm3 (p-value: 0.017),
and pertuzumab reduced to 301.0 ± 62.9 mm3. Interestingly, superior (and more rapid) tumor
regression was achieved by dual FASN and HER2 blockade (87.2 ± 38.2 mm3; p-valuevsEGCG:
0.017 and p-valuevsPertu: 0.010), compared with EGCG or pertuzumab as single agents (Fig 4A,
left panel). Despite the absence of complete tumor shrinkage, combinatorial treatment signifi-
cantly reduced tumor growth in the HER2-PDX model. Under the same schedule, in the
HER2-PDXRmodel EGCG (30 mg/kg for 3d/w) and pertuzumab (30 mg/kg/once weekly) also
reduced tumor growth after 24 days of treatment (Fig 4A, right panel), but in vivo efficacy of
the dual FASN and HER2 blockade was also superior (and more rapid) compared with EGCG
and pertuzumab as a single agents. Compared with the control group (393.9 ± 95.5 mm3),
EGCG and pertuzumab decreased tumor growth to 285.9 ± 36.5 mm3 and 310.4 ± 34.5 mm3,
respectively. The combination of EGCG with pertuzumab significantly reduced tumor growth
up to 177.64 ± 34.5 mm3 (p-valuevsEGCG: 0.030 and p-valuevsPertu: 0.008).
Regarding mTOR and FASN inhibition in vivo, EGCG (30 mg/kg for 3d/w) reduced tumor
growth in the HER2-PDX model after 21 days of treatment (Fig 5A, left panel). Control ani-
mals achieved a median tumor growth of 386.4 ± 66.7 mm3 whereas EGCG median tumor
growth was significantly reduced to 183.3 ± 15.1 mm3 (p-value: 0.017). Despite the strong anti-
tumor activity exhibited by temsirolimus when used as a single agent (18.0 ± 15.1 mm3; p-
value: 0.000), its activity was little enhanced (day 21) by the addition of EGCG. Combination of
temsirolimus with EGCG not only reduced tumor ratio of growth, but also achieved tumor
shrinkage compared with the initial tumor volume (-8.2 ± 6.0 mm3). In the trastuzumab plus
lapatinib-resistant HER2-PDX model EGCG treatment decreased the median tumor growth
(231.8 ± 38.4 mm3) compared with control group (314.8 ± 81.1 mm3) at the end of the experi-
ment (Fig 5A, left panel). In the HER2-PDXRmodel, temsirolimus significantly decreased
tumor growth when used as a single agent (114.3 ± 27.1 mm3; p-value: 0.045), and its activity
was enhanced by the addition of EGCG (94.9 ± 33.1 mm3). These results show that temsiroli-
mus could have a relevant effect in patients with HER2 breast cancer, even those that have pro-
gressed to anti-HER2 therapies, and combination with FASN-inhibitors could even assist
temsirolimus to achieve tumor depletion.
Tumor samples from HER2-PDX and HER2-PDXR treated tumors showed an increased
apoptosis compared with HER2-PDX and HER2-PDXR control tumors, assessed by fluorescent
TUNEL assay (Figs 4B and 5B). EGCG, pertuzumab and temsirolimus used as single agents
induced apoptosis in HER2-PDX (133±14 TUNEL+ cells/mm2, 122±16 TUNEL+ cells/mm2
and 333±19 TUNEL+ cells/mm2, respectively) and HER2-PDXR (337±19 TUNEL+ cells/mm2,
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Fig 4. EGCG, alone or combined with pertuzumab, inhibits tumor growth of sensitive and resistant HER2+ orthoxenopatients. (a)Mice bearing
HER2-PDX and resistant HER2-PDX (HER2-PDXR) were treated with control (C), EGCG (30 mg/kg, 3 days a week), pertuzumab (30 mg/kg, 1 day a week)
or the combination (EGCG plus pertuzumab) for 24 days. Dots are mean of each experimental group and bars, SE. * (p 0.05), ** (p 0.01) and ***
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352±18 TUNEL+ cells/mm2 and 803±36 TUNEL+ cells/mm2, respectively) tumors compared
with apoptosis showed by untreated HER2-PDX (66±8 TUNEL+ cells/mm2) and HER-PDXR
(287±23 TUNEL+ cells/mm2) tumors. Combinatory treatments (pertuzumab plus EGCG and
temsirolimus plus EGCG) increased the apoptosis in HER2-PDX (933±40 TUNEL+ cells/mm2
and 1265±51 TUNEL+ cells/mm2, respectively) and HER2-PDXR (866±40 TUNEL+ cells/mm2
and 1197±55 TUNEL+ cells/mm2, respectively) tumors compared with each single treatment
alone.
Previous first-generation of FASN inhibitors such as C75 and cerulenin have been limited
by inducing severe body weight loss, which is thought to be related to a parallel stimulation of
fatty acid oxidation by these inhibitors [24, 37]. But we have previously reported that animals
treated with EGCG didn’t display neither change on body weight nor on hepatic, renal and
haematological function serum markers compared to control animals [19]. In this study,
animals treated with EGCG and also with pertuzumab and temsirolimus (alone or in combina-
tion) were weighed daily to evaluate in vivo body weight effect. With respect to control animals,
we identified no significant changes on food and fluid intake or body weight after treatment
with EGCG, pertuzumab and temsirolimus alone or in combination (Figs 4C and 5C).
Histological studies (Hematoxylin-Eosin) of liver, lung, kidney and heart showed no tissue
structural abnormalities between control and treated animals in both HER2-PDX models (S6,
S7 and S8 Figs).
Discussion
Despite the remarkable success of anti-HER2 therapies, patients with advanced HER2-positive
breast cancer frequently display primary resistance and, in patients initially sensitive to these
agents, acquired resistance may emerge over time [9, 10]. To date, even several mechanisms of
resistance to anti-HER2 agents are known, this clinical problem is not fully understood. Here,
we have developed and characterized stable cell lines derived from the HER2-positive SKBr3
cells that are resistant to either trastuzumab (SKTR), lapatinib (SKLR) or both (SKLTR). Some
molecular mechanisms of resistance in our developed anti-HER2 resistant models are consis-
tent with the previously described [8–16]. One of the commonly described mechanisms of
anti-HER2 therapies is the overexpression of other RTKs or their ligands. Thus, it has been
reported that HER3 overexpression leads to HER2/HER3 heterodimer formation consequently
activating the PI3K/AKT/mTOR pathway [6]. Conversely, our trastuzumab, lapatinib and tras-
tuzumab plus lapatinib resistant models show a decrease in HER3 expression and activation,
whereas an overexpression of EGFR and increased expression levels of EGFR (EGF and TGF-
α) and EGFR-HER4 (EREG and HB-EGF) ligands. This is consistent with several reports that
show EGFR overexpression (and its ligands) in trastuzumab resistant SKBr3 cells and in xeno-
graft models of acquired trastuzumab and lapatinib resistance [38–40]. Even more, after dual
trastuzumab and lapatinib long-term exposure, our patented SKLTR [41] cells overexpressed
HER4 besides EGFR, and increased the expression of EGFR (EGF and AR) and EGFR-HER4
(BTC, EREG and HB-EGF) ligands to overcome the anticancer effects of both anti-HER2
agents. In a clinical study, constitutive presence of HER4 has been directly related with sensitiv-
ity to anti-HER2 drugs in breast cancer [42] whereas in prostate cancer an increase of HER4
expression has been shown to be responsible of resistance to the EGFR inhibitor erlotinib [43].
(p 0.001). (b) Apoptosis, by TUNEL fluorescent assay, was perfomed in control (C), EGCG (E), pertuzumab (P) and combination (P+E) treated as in (A)
tumors. Tumors were collected at the end of the experiment and fixed in paraffin. Pictures are representative of two samples of each group. (c) Body weight
of the mice treated as in (A). Data are expressed as body weight at the end of the experiment and boxes show the 25th to 75th percentiles, whereas whiskers
extend to the 5th and 95th percentiles.
doi:10.1371/journal.pone.0131241.g004
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Fig 5. EGCG, alone or combined with temsirolimus, inhibits tumor growth of sensitive and resistant HER2+ orthoxenopatients. (a)Mice bearing
HER2-PDX and resistant HER2-PDX (HER2-PDXR) were treated with control (C), EGCG (30 mg/kg, 3 days a week), temsirolimus (10 mg/kg, 1 day
a week) or the combination (EGCG plus temsirolimus) for 21 days. Dots are mean of each experimental group and bars, SE. * (p 0.05), ** (p 0.01) and
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Our findings highlight that HER4 overexpression and activation could be a new molecular
mechanism of resistance to anti-HER2 therapies.
Changes in HER2 downstream proteins (such as loss of PTEN, PI3K mutations/hyperacti-
vation, AKT overexpression and hyperactivation) have also been identified as resistant mecha-
nisms to trastuzumab and lapatinib therapies [14–16]. In patients treated with trastuzumab,
activating mutations of PI3K (PI3KCA) were associated with poor response and survival [44].
Eichhom PJ et al also reported PI3KCAmutations as responsible of lapatinib resistance [15]. In
this study, we have shown that although PI3KCAmutations (PIK3CA_E545K mutation in
SKTR cells and PIK3CA_E542K mutation in SKLR and SKLTR cells) have not enough inci-
dence to show effects in AKT activation, they collaborate with RTKs changes and downstream
loops in order to maintain PI3K/AKT/ mTOR pathway activation in trastuzumab, lapatinib
and also in a trastuzumab plus lapatinib resistant cells. Lapatinib effects have been described to
be mediated preferentially through the MAPK/ERK pathway through Ras overexpression or
mutation [45]. Accordingly, in our study ERK1/2 overactivation is also shown to be another
downstream change that leads to cell proliferation signaling of the resistant cells. No significant
changes in mTOR and p-mTOR proteins were observed in our long-term resistant cells.
Although the main pathway related to mTOR is the PI3K/AKT axis, mTOR is a downstream
in which several signaling pathways converge. In addition, this pathways act as a complex net-
work, and activation of one important effector can be accomplished by several emissaries. Even
with decreased activation of AKT in our resistant models, maintenance of mTOR activation
can be accomplished by direct signaling of PI3K to mTOR, bypassing AKT [46]. Also, it is
described that MAPK inhibit the tuberous sclerosis complex (TSC1/TSC2), which in turn
inhibits mTOR activation [47].
Together, overactivation of HER2 in SKLR and SKLTR cells and maintenance of mTOR, p-
mTOR and FASN expression in all the resistant models provided the rationale to test combined
FASN and HER2 or mTOR pathways blockade in this setting. We found that the simultaneous
treatment of parental and resistant (SKTR, SKLR and SKLTR) cells with anti-FASN com-
pounds (EGCG and the novel derivative G28UCM) plus pertuzumab improved the effects of
each drug alone in SKLTR. But, inhibiting mTOR, the downstream target of HER2 pathway in
combination with FASN inhibition resulted in a strong synergistic interaction in all parental
and resistant cells. G28UCM, the novel FASN inhibitor, also improved combinatorial effect of
EGCG, producing much more synergism between temsirolimus and G28UCM. We had previ-
ously shown that G28UCM improved EGCG effects, alone and in several combinatorial regi-
ments with anti-HER2 drugs and chemotherapy, in parental and trastuzumab- or lapatinib-
resistant AU565 HER2 breast cancer cells [29]. Several studies have used mTOR inhibition to
overcome resistance to HER2-targeted therapies [48] and it has already been assayed in
women with trastuzumab-resistance [49]. It has also been shown the synergism between
mTOR and FASN inhibition to induce cytotoxicity in ER/HER2-positive breast cancer cell
lines [50]. These in vitro results support the rationale to test in vivo the antitumor efficacy of
these agents in a combination regimen in tumors resistant to anti-HER2 therapies.
In previous preclinical studies conducted in nude mice bearing HER2 cells, we and others
showed that EGCG displayed in vivo antitumor activity without decreasing food intake and
induction of weight loss [24, 37]. This is the first study that attempt to evaluate the in vivo
*** (p 0.001). (b) Apoptosis, by TUNEL fluorescent assay, was perfomed in control (C), EGCG (E), temsirolimus (T) and combination (T+E) treated as in
(A) tumors. Tumors were collected at the end of the experiment and fixed in formalin. Pictures are representative of two samples of each group. (c) Body
weight of the mice treated as in (A). Data are expressed as body weight at the end of the experiment and boxes show the 25th to 75th percentiles, whereas
whiskers extend to the 5th and 95th percentiles.
doi:10.1371/journal.pone.0131241.g005
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efficacy and feasibility of dual blockade of FASN and the HER2 signaling pathway in HER2-po-
sitive patient tumor samples (HER2-PDX) and in HER2 samples of a patient who relapsed
after trastuzumab and lapatinib therapies (HER2-PDXR). Here, we report the validity of this
approach clearly showing that the combination of EGCG with pertuzumab and temsirolimus
resulted in synergistic reduction of HER2-PDX and HER2-PDXR tumors, without signs of tox-
icity (weight loss) related to in vivo antitumor efficacy experiments using anti-FASN com-
pounds [24, 28, 29]. Reduction of tumor growth could be accomplished, in part, by an
apoptotic event. Increase of apoptosis has been seen in parental and resistant tumor samples
treated with EGCG, pertuzumab and temsirolimus. As synergism in tumor reduction after
combinatorial treatments, apoptosis has also been synergistically increased when combining
EGCG with pertuzumab or temsirolimus. These similar profiles in tumor growth reduction
and apoptosis suggest that apoptosis is responsible for tumor growth inhibition. In fact, we had
previously shown that EGCG produces apoptosis in vitro and in vivo [18, 19, 28, 37]. Apoptosis
is also consistent with other studies of pertuzumab in cells and mouse models [51, 52]. Temsir-
olimus has been shown to produce apoptosis in a resistant oropharyngeal carcinoma cell line
[53], colorectal cancer cells [54] and other cancers. But little, if any, apoptosis has been seen in
different breast cancer cell lines treated with temsirolimus [55]. In this study, we demonstrate
that tumor growth inhibition in HER2 breast cancer PDX (non-resistant and resistant) occurs
by apoptotic event in tumoral cells, and this is consistent what have been found in other types
of cancer. These findings, accordingly with those obtained in vitro, encourages us to think that
combining FASN inhibitors with temsirolimus or pertuzumab could be one example of a
potential combinatorial available in the clinical management of HER2-positive breast cancer
patients who progressed to standard treatments.
In this study, we have developed novel mono- and dual- long term trastuzumab plus lapati-
nib resistant breast cancer models to find out new pharmacological strategies to overcome this
setting. Then, we have showed in vitro and in vivo that the inhibition of FASN, alone or in
combination with anti-HER2 signaling drugs (temsirolimus and pertuzumab), could have rele-
vant clinical implications in patients who fail to respond to current therapies.
In summary, our findings provide a rationale for the preclinical development of inhibitors
of FASN activity in combination with anti-HER2 signaling agents in breast cancer refractory to
anti-HER2 therapies.
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tured under the same conditions, without treatment for 12 or 24 hours. Equal amounts of
lysates were immunoblotted with anti-PARP antibody. Blots were reproved for β-actin as load-
ing control.
(DOCX)
S4 Fig. Effect of EGCG with pertuzumab and temsirolimus combinations in parental and
resistant cells. a) SKBr3 (SK) parental cells and b) trastuzumab-resistant SKBr3 (SKTR), c)
lapatinib-resistant SKBr3 (SKLR) and d) lapatinib plus trastuzumab-resistant SKBr3 (SKLTR)
cells were treated with trastuzumab (T; 2 μM), lapatinb (L; 3 μM), EGCG (250 μM), pertuzu-
mab (5 μg/ml) and temsirolimus (Temsi; 12 μM) for 12 and 24 hours. Control cells were cul-
tured under the same conditions, without treatment for 12 or 24 hours. Equal amounts of
lysates were immunoblotted with anti-FASN and anti-mTOR antibodies. Blots were reproved
for β-actin as loading control.
(DOCX)
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S5 Fig. HER2 PDX-tumors characterization. SKBr3 (SK) parental cells and tumors from
HER2-PDX and HER2-PDXR were lysed and equal amounts of lysates were immunoblotted
with anti-HER2, anti-FASN and anti-mTOR antibodies.
(DOCX)
S6 Fig. EGCG, alone or combined with pertuzumab, does not induce liver and heart toxic-
ity in xenografts.Histological analysis studies (Hematoxylin-Eosin) of liver and heart showed
no tissue structural abnormalities between control and treated animals in both non-resistant
and resistant HER2-PDX models. At least 2 mice per group were analyzed and image shown is
representative of each group.
(DOCX)
S7 Fig. EGCG, alone or combined with temsirolimus, does not induce liver and heart toxic-
ity in xenografts.Histological analysis studies (Hematoxylin-Eosin) of liver and heart showed
no tissue structural abnormalities between control and treated animals in both non-resistant
and resistant HER2-PDX models. At least 2 mice per group were analyzed and image shown is
representative of each group.
(DOCX)
S8 Fig. EGCG, alone or combined with pertuzumab and temsirolimus, does not induce kid-
ney and lung toxicity in xenografts.Histological analysis studies (Hematoxylin-Eosin) of kid-
ney and lung showed no tissue structural abnormalities between control and treated animals in
both non-resistant and resistant HER2-PDX models. At least 2 mice per group were analysed
and image shown is representative of each group.
(DOCX)
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